Global Blood Therapeutics (GBT) Gets a Hold Rating from William Blair

In a report released today, Raju Prasad from William Blair maintained a Hold rating on Global Blood Therapeutics (GBTResearch Report). The company’s shares closed last Thursday at $29.60.

According to, Prasad is a 4-star analyst with an average return of 12.5% and a 50.8% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Crispr Therapeutics AG, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Global Blood Therapeutics is a Moderate Buy with an average price target of $80.67, implying a 164.5% upside from current levels. In a report released today, Piper Sandler also maintained a Hold rating on the stock with a $45.00 price target.

See today’s analyst top recommended stocks >>

Global Blood Therapeutics’ market cap is currently $1.9B and has a P/E ratio of -7.60. The company has a Price to Book ratio of 5.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.